Table 2 The significantly enriched GO terms associated with pain in sheep
Go term | Count | P value | Gene |
|---|---|---|---|
Up-regulated | |||
 GO:0015276 ~ ligand-gated ion channel activity | 14 | 2.48E−05 | GABRG3, SHROOM2, GRIK1, GABRB2, GLRA3, GABRB1, GRIN2A, GRIA4, CNGB3, KCNJ6, GRID2, CHRNA5, KCNH7, SCNN1B |
 GO:0006811 ~ ion transport | 34 | 2.10E−03 | SLC5A5, GRIK1, GABRB2, ATOX1, GABRB1, GLRA3, SLC39A12, ATP5G1, CNGB3, CHRNA5, GRID2, SLC30A3, SCNN1B, ATP5I, OCA2, SLC30A7, TRPM3, GABRG3, KCND2, KCNB2, SLC12A3, GRIN2A, GRIA4, CACNG2, TCN1, ATP13A4, SLCO1B3, KCNJ6, CATSPER3, KCNH7, HEPH, KCTD16, SLC13A4, CLCN7 |
 GO:0022836 ~ gated channel activity | 20 | 4.61E−04 | GABRG3, SHROOM2, KCND2, GRIK1, GABRB2, KCNB2, GLRA3, GABRB1, GRIN2A, CACNG2, GRIA4, CNGB3, KCNJ6, CATSPER3, GRID2, CHRNA5, KCNH7, KCTD16, SCNN1B, CLCN7 |
 GO:0005216 ~ ion channel activity | 21 | 0.002572 | TRPM3, GABRG3, SHROOM2, KCND2, GRIK1, GABRB2, KCNB2, GLRA3, GABRB1, GRIN2A, CACNG2, GRIA4, CNGB3, KCNJ6, CATSPER3, GRID2, CHRNA5, KCNH7, KCTD16, SCNN1B, CLCN7 |
 GO:0060284 ~ regulation of cell development | 4 | 0.895878 | MUSK, MAP1B, NLGN1, SOX5 |
 GO:0007268 ~ synaptic transmission | 15 | 0.020093 | GABRG3, KCND2, MYO6, GRIK1, GABRB2, GLRA3, PCDHB4, NLGN1, GRIN2A, GRIA4, MUSK, GRID2, CHRNA5, GAD1, NPFF |
 GO:0019226 ~ transmission of nerve impulse | 16 | 0.033585 | GABRG3, KCND2, MYO6, GRIK1, GABRB2, GLRA3, PCDHB4, NLGN1, GRIN2A, CACNG2, GRIA4, MUSK, GRID2, CHRNA5, GAD1, NPFF |
 GO:0006812 ~ cation transport | 22 | 0.042508 | TRPM3, SLC5A5, KCND2, KCNB2, SLC12A3, ATOX1, SLC39A12, GRIN2A, CACNG2, ATP5G1, TCN1, ATP13A4, KCNJ6, CATSPER3, KCNH7, HEPH, KCTD16, SLC30A3, SLC13A4, SCNN1B, ATP5I, SLC30A7 |
 IPR001508:NMDA receptor | 4 | 0.009544 | GRIK1, GRID2, GRIN2A, GRIA4 |
 GO:0005254 ~ chloride channel activity | 5 | 0.116044 | GABRG3, GABRB2, GABRB1, GLRA3, CLCN7 |
 GO:0005244 ~ voltage-gated ion channel activity | 9 | 0.134055 | KCND2, KCNJ6, CATSPER3, KCNB2, GRIN2A, KCNH7, CACNG2, KCTD16, CLCN7 |
 GO:0031404 ~ chloride ion binding | 5 | 0.138619 | GABRG3, GABRB2, GABRB1, GLRA3, CLCN7 |
Down-regulated | |||
 GO:0005248 ~ voltage-gated sodium channel activity | 9 | 2.43E−06 | SCN2B, SCN3B, PKD2, SCN9A, SCN4B, SCN11A, SCN8A, SCN7A, SCN10A |
 GO:0001518 ~ voltage-gated sodium channel complex | 7 | 6.00E−05 | SCN2B, SCN9A, SCN4B, SCN11A, SCN8A, SCN7A, SCN10A |
 GO:0031402 ~ sodium ion binding | 21 | 1.81E−04 | SLC8A3, SLC13A5, PDXK, SCN2B, SLC12A2, SCN3B, ATP1B2, SLC9A3, KIAA1919, SLC34A2, SLC17A6, SLC6A8, SCN9A, SLC4A8, SCN4B, SLC13A3, SCN11A, SCN7A, SCN8A, HCN4, SCN10A |
 GO:0022843 ~ voltage-gated cation channel activity | 19 | 0.015225 | KCNJ16, KCNAB2, SCN2B, SCN3B, KCNA2, KCTD20, KCNJ5, KCTD9, KCNK6, SCN9A, PKD2, SCN4B, SCN11A, SCN7A, SCN8A, KCNQ2, HCN4, KCTD12, SCN10A |
 hsa04080:neuroactive ligand-receptor interaction | 10 | 0.978027 | GABRG2, GABRE, HTR1B, PTGER3, TRPV1, P2RY1, LTB4R2, AVPR1A, GABBR2, PTAFR |
 GO:0005083 ~ small GTPase regulator activity | 36 | 4.43E−04 | ALS2, TBC1D9, CYTH1, PREX1, MYO9B, CYTH3, ARFGEF2, RIMS1, PLEKHG3, PLEKHG2, DMXL2, PLEKHG7, SOS1, GOPC, ARHGAP1, TBC1D13, PLEKHG5, RAPGEF2, FGD5, ERRFI1, IQSEC1, TBC1D2B, ABR, TRIO, RPH3A, VAV2, ARHGEF10, MAP4K4, TBC1D24, CDC42BPG, ADAP2, SGSM1, SGSM2, CIT, CDC42BPB, RANBP10 |
 GO:0008076 ~ voltage-gated potassium channel complex | 7 | 0.526697 | KCNJ5, KCTD9, KCNK6, KCNA2, KCTD20, KCNQ2, KCTD12 |
 GO:0006952 ~ defense response | 33 | 0.971848 | ALS2, YWHAZ, C3, TRPV1, TLR2, AFAP1L2, CX3CL1, ITGB1, TLR7, IL31RA, FCN3, SCN9A, THBS1, MX2, FN1, SPP1, PTGER3, LIPA, IL1RL1, SAAL1, SOCS6, SMAD1, CD1D, DDX58, SIGLEC1, ABCC9, SARM1, CCR5, TFRC, CCR2, ICOSLG, CD14, PTAFR |